CIK 0002035832 · <br>Emerging growth company
Aktis Oncology, Inc.
Sign in to watch- Ticker
- AKTS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 852584233
- Phone
- 978-237-4380
- Business address
- 17 DRYDOCK AVENUE, SUITE #17-401, BOSTON, MA, 02210
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $258,621
- in 1 filing, $259K under 10b5-1 plans
Net −$258,621. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-08 | Czibere Akos Chief Medical Officer | Sale | −30,829 | $27.95 | $862K | 4,371 |
| 2026-07-08 | Czibere Akos Chief Medical Officer | Sale | −4,371 | $28.71 | $125K | 0 |
| 2026-07-08 | Czibere Akos Chief Medical Officer | Option exercise · Stock Option (Right to Buy) | −50,000 | 221,218 | ||
| 2026-04-15 | Gormley Glenn Director | Grant or award · Stock Option (Right to Buy) | +37,866 | 37,866 | ||
| 2026-01-12 | Foley Todd Director | Conversion | +597,391 | 597,391 | ||
| 2026-01-12 | Foley Todd Director | Conversion | +2,688,270 | 3,285,661 | ||
| 2026-01-12 | Foley Todd Director | Conversion | +716,872 | 4,002,533 | ||
| 2026-01-12 | Foley Todd Director | Purchase | +232,870 | $18.00 | $4.2M | 4,235,403 |
| 2026-01-12 | Foley Todd Director | Conversion · Series Seed Redeemable Convertible Preferred Stock | −2,272,727 | 0 | ||
| 2026-01-12 | Foley Todd Director | Conversion · Series A Redeemable Convertible Preferred Stock | −10,227,273 | 0 | ||
| 2026-01-12 | Foley Todd Director | Conversion · Series B Redeemable Convertible Preferred Stock | −2,727,273 | 0 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion | +1,314,262 | 1,655,971 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion | +5,914,197 | 7,570,168 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion | +1,577,119 | 9,147,287 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Purchase | +1,112,777 | $18.00 | $20.0M | 10,260,064 |
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion · Series Seed Redeemable Convertible Preferred Stock | −5,000,000 | 0 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion · Series A Redeemable Convertible Preferred Stock | −22,500,000 | 0 | ||
| 2026-01-12 | MPM BIOVENTURES 2018, L.P. 10% owner | Conversion · Series B Redeemable Convertible Preferred Stock | −6,000,000 | 0 | ||
| 2026-01-12 | GADICKE ANSBERT 10% owner | Conversion | +1,314,262 | 1,655,971 | ||
| 2026-01-12 | GADICKE ANSBERT 10% owner | Conversion | +5,914,197 | 7,570,168 |
Page 2 of 4 · 76 trades